Yu Cheng-Chia, Hu Fang-Wei, Yu Chuan-Hang, Chou Ming-Yung
School of Dentistry, Chung Shan Medical University, Taichung, Taiwan.
Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan.
Head Neck. 2016 Apr;38 Suppl 1:E231-8. doi: 10.1002/hed.23975. Epub 2015 Jun 4.
Oral squamous cell carcinoma (OSCC) is one of the most common cancers in the world. Previously, we enriched a subpopulation of OSCC-derived cancer stem cells (OSCC-CSCs), and identified CD133 as an OSCC-CSC marker.
We determined the function of CD133 on chemosensitivity of oral cancer CSCs by silencing CD133.
Initially, we observed that the expression profile of CD133 in OSCC-side population (OSCC-SPs) cells, which exerted properties of CSCs, was significantly upregulated than that of major population (MPs) cells of OSCCs. The cell viability experiments showed that SPs were more chemoresistant compared with major populations. Importantly, targeting CD133 ameliorated the drug resistance of OSCC-SPs to cisplatin treatment. Targeting CD133 and cisplatin co-treatment led to the maximal inhibition on tumor initiating properties in OSCC-SPs.
Side population cells with CSCs properties existed in OSCCs, and silencing CD133 exhibited a prominent therapeutic effect in enhancing the sensitivity of chemotherapy in OSCC through elimination of CSCs. © 2015 Wiley Periodicals, Inc. Head Neck 38: E231-E238, 2016.
口腔鳞状细胞癌（OSCC）是世界上最常见的癌症之一。此前，我们富集了OSCC来源的癌症干细胞（OSCC-CSCs）亚群，并将CD133鉴定为OSCC-CSC标志物。
我们通过沉默CD133来确定其对口腔癌CSCs化疗敏感性的作用。
最初，我们观察到具有CSCs特性的OSCC侧群（OSCC-SPs）细胞中CD133的表达谱比OSCC主要群体（MPs）细胞显著上调。细胞活力实验表明，与主要群体相比，SPs具有更强的化疗抗性。重要的是，靶向CD133可改善OSCC-SPs对顺铂治疗的耐药性。靶向CD133与顺铂联合治疗对OSCC-SPs的肿瘤起始特性产生最大抑制作用。
OSCC中存在具有CSCs特性的侧群细胞，沉默CD133通过消除CSCs在增强OSCC化疗敏感性方面显示出显著的治疗效果。©2015威利期刊公司。《头颈》38：E231-E238，2016年。
